Key Sessions
Check out the highlights below.
The Payer Landscape
From white and brown bagging, to home infusion, vertical integration and beyond, the payer landscape is constantly changing. During this session, Kathryn Tong, Vice President, Managed and Value Based Care, Pharmacy and Analytics, covered the top current payer trends impacting oncology practices, including step therapy restrictions, prior authorization requirements, national payer policy changes, and white/brown/clear bagging.
Ask how we can help you navigate the payer landscape
Optimizing your Onmark GPO Membership
The mission of the Onmark GPO is to ensure that members experience the best economic value and differentiated services. During the Summit, the GPO team shared innovative approaches to contract negotiations, their strategy for navigating drug pricing challenges and a four-phase strategy for the launch of biosimilars. The Onmark GPO has recognized more than $1.1B in savings and performance-based rebates to members, supporting more than 10,000 physicians with $10.7B in annual drug spend.
Explore the Onmark GPO
Public Policy Update
Ben Jones, Vice President of Government Relations and Public Policy, kicked off his session with an overview of the current public policy landscape, including how COVID-19 has reshaped the policy landscape and election priorities. He covered the potential impact of the upcoming presidential elections, provided an overview of select executive orders, and the longer-term impact of COVID-19 on insurance status.
Discover more policy resources
Interactive Breakout Sessions
Attendees also had the opportunity to join interactive breakout sessions led by our members and McKesson experts to:
- Discover how to take your in-office dispensing business to the next level
- Maximize your practice’s financial counseling program
- Discuss the new “COVID-19 Normal”
- Hear the latest on McKesson technology, including updates and enhancements
- Understand how to diversify their oncology practice’s revenue streams
- Implement biosimilars using best practices for adoption
Other highlights
While the Summit agenda was jam-packed, attendees also participated in virtual networking sessions where they discussed technology, biosimilars and more with McKesson experts and their peers. Attendees also visited event sponsors and exhibitors in the virtual exhibit hall.